MHRA Adds BPC-157 to Substances Under Surveillance

The UK Medicines and Healthcare products Regulatory Agency has added BPC-157 (Body Protection Compound-157) to its list of substances under active surveillance. The move places BPC-157 alongside a number of other synthetic peptides that the agency is monitoring for patterns of adverse event reporting, unlicensed sale, and misleading health claims.

BPC-157 is a synthetic pentadecapeptide derived from a protein found in human gastric juice. It is not licensed as a medicine in any jurisdiction and has no approved therapeutic indications. Despite this, the compound has become one of the most widely discussed peptides in the research compound market, with a substantial body of preclinical literature suggesting potential effects on tissue repair, angiogenesis, and gastrointestinal protection.

The MHRA's surveillance designation does not constitute a ban or a scheduling change. Products containing BPC-157 remain in a regulatory grey area in the UK — they cannot be legally sold as medicines or with therapeutic claims, but possession for personal research use is not specifically prohibited. The surveillance designation means the agency will be actively collecting data on the compound, monitoring online retail activity, and assessing whether further regulatory action is warranted.

Industry observers note that increased regulatory attention to research peptides has been a trend across multiple jurisdictions since 2024, driven by the growing consumer market for compounds that have not undergone formal clinical evaluation.